Blood:甲状腺激素通过TR-KLF9轴调节造血功能。

2017-09-26 qinqiyun MedSci原创

先天性甲状腺功能减退(CH)是一种最常发生的内分泌疾病,常伴有贫血和免疫缺陷,而其机制尚未完全清楚。

中心点:

通过ENU突变建立的重度甲状腺功能减退的猪模型表现出人类患者的临床特点。

KLF9是甲状腺素轴和造血功能间的关键调控。

摘要:

先天性甲状腺功能减退(CH)是一种最常发生的内分泌疾病,常伴有贫血和免疫缺陷,而其发病机制尚未完全清楚。

现研究人员在迷你猪上通过乙基亚硝脲(ENU)诱导突变建立重度CH合并贫血和T淋巴细胞减少的模型来模拟甲状腺减退患者的临床特征。经鉴定认为一个新发阴性突变c.l226A>G 是致病突变。该突变阻碍过氧化氢(H2O2)的产生,从而导致甲状腺激素(TH)合成失败。

胸腺的转录本分析发现Krüppel样因子9(KLF9)在甲状腺功能减退突变中标的达显著下调。已证实,KLF9在体内和体外的TH受体(TR)依赖性通路中直接受TH调控。

而且,在斑马鱼胚胎中敲除klf9,可破坏造血发育,如红细胞的成T淋巴细胞的发生。

研究结果表明TR-KLF9轴对于造血功能障碍至关重要,或许可以就此开发新的治疗状腺疾病的干预方法。

原始出处:

Ying Zhang,et al.Thyroid hormone regulates hematopoiesis via the TR-KLF9 axis.Blood.September 25,2017. https://doi.org/10.1182/blood-2017-05-783043

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=287947, encodeId=bc2928e947e5, content=全文在哪里找呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa472271494, createdName=121a6d93m71暂无昵称, createdTime=Wed Feb 14 18:40:22 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248498, encodeId=94b42484986a, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 28 10:24:07 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494562, encodeId=36c3149456241, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Sep 28 07:24:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247932, encodeId=a75e24e932ec, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:00:57 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2018-02-14 121a6d93m71暂无昵称

    全文在哪里找呀

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=287947, encodeId=bc2928e947e5, content=全文在哪里找呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa472271494, createdName=121a6d93m71暂无昵称, createdTime=Wed Feb 14 18:40:22 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248498, encodeId=94b42484986a, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 28 10:24:07 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494562, encodeId=36c3149456241, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Sep 28 07:24:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247932, encodeId=a75e24e932ec, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:00:57 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-28 大爰

    学习了谢谢分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=287947, encodeId=bc2928e947e5, content=全文在哪里找呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa472271494, createdName=121a6d93m71暂无昵称, createdTime=Wed Feb 14 18:40:22 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248498, encodeId=94b42484986a, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 28 10:24:07 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494562, encodeId=36c3149456241, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Sep 28 07:24:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247932, encodeId=a75e24e932ec, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:00:57 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-28 俅侠
  4. [GetPortalCommentsPageByObjectIdResponse(id=287947, encodeId=bc2928e947e5, content=全文在哪里找呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa472271494, createdName=121a6d93m71暂无昵称, createdTime=Wed Feb 14 18:40:22 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248498, encodeId=94b42484986a, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 28 10:24:07 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494562, encodeId=36c3149456241, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Sep 28 07:24:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=247932, encodeId=a75e24e932ec, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3da1990174, createdName=yfjms, createdTime=Tue Sep 26 19:00:57 CST 2017, time=2017-09-26, status=1, ipAttribution=)]
    2017-09-26 yfjms

    学习了

    0

相关资讯

Sci Rep:日化用品会让我们的智商越来越低吗?

对所有的脊椎动物而言,甲状腺激素一直在调节大脑生长发育过程中扮演着重要角。但是,现代生活中接触到的越来越多的日化用品却阻碍了甲状腺激素在人类大脑发育中的关键作用。

NEJM:老年亚临床甲状腺功能减退症患者甲状腺激素治疗效果如何?

由此可见,左旋甲状腺素并未为亚临床甲状腺功能减退的老年人提供任何明显的好处。

盘点:甲状腺激素水平对人体健康的影响

【1】Thyroid:缺乏甲状腺激素,大脑会发生什么变化?近期发表在Thyroid的研究称,甲状腺全切术后急性甲状腺功能低下的状态时,局部大脑功能连通性增加。韩国蔚山大学医学院的Won Bae Kim博士和同事对21名因甲状腺癌行甲状腺全切术的患者进行了一项研究,探究撤出甲状腺激素是否会影响静息状态的大脑功能连通性,以及大脑功能连通性的改变是否与情绪和生活质量有关。研究者写道:“研究结果表明,

Clin Endocrinol:孕期肥胖与产妇和新生儿的甲状腺素水平有关

在肥胖的妊娠女性中,肥胖的发生与甲状腺激素(TH)的水平有关。妊娠期间适当水平的甲状腺激素的维持对于胎儿的发育非常重要。本研究的目的是测定产妇外周血及相匹配的正常体重、超重和肥胖产妇脐带血中FT3、FT4和TSH水平,明确产妇和新生儿TH水平改变。FT3、FT4和TSH水平的检测采用ELISA。所有数据根据孕早期的BMI分层比较。研究结果显示,随着产妇肥胖水平的增加,新生儿和产妇的FT3逐渐增加,

甲状腺激素水平高,增加心源性猝死风险!

对于甲亢患者来说,由于血液中高浓度甲状腺激素能增强心肌细胞对儿茶酚胺的敏感性,从而使心肌收缩力增强、耗能增加。由于心脏长期处于高负荷状态,导致心脏增大、心律失常、心力衰竭,甚至有心源性猝死(SCD)的危险。其实,这种临床现象被称为“甲亢心”,目前已经被认识并重视。但是对于甲状腺激素浓度在正常区间的人来说,他们SCD的风险会不会随着甲状腺激素的水平有所变呢?近期,国际心血管权威杂志《Circulat

JCEM:甲功里的这项指标与肺癌、乳腺癌风险有关

体外和体内实验均表明,甲状腺激素中存在抑癌和致癌的成分,但是基于人群的研究却得出不一致的结果。 本项以人群为基础的研究目的是,前瞻性评估甲状腺功能和癌症发生情况之间的关系。 该研究是一项基于人群的前瞻性队列研究,纳入了10318名参与者,基线测量游离甲状腺素(FT4)和/或促甲状腺激素(TSH)。 使用Cox比例风险模型来评估任何非皮肤癌的实体肿瘤风险;以及细分为肺癌、乳腺癌、前